- Datum19.04.2024
- UhrzeitLäuft gerade
- VeranstalterXTB
Du willst selbst ins Charting einsteigen?
Nutze das Charting-Widget auf dem stock3 Terminal für Deine eigene Analyse. Mehr Features. Mehr Werkzeuge. Mehr stock3.
Chart im Terminal öffnenDaiichi Sankyo Co. Ltd. Kurse
Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
---|---|---|---|---|---|---|
L&S | VK | |||||
Tradegate | VK | |||||
Stuttgart | VK |
Passende Produkte
WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
---|
Wertentwicklung (L&S)
Wikifolio
Passender Service zu Daiichi Sankyo Co. Ltd.
Webinar zu Daiichi Sankyo Co. Ltd.
Kursinformationen (L&S)
- Tagestief / Hoch (€)-
- 52W-Tief / Hoch (€)22,290-34,210
- Jahrestief / Hoch (€)24,470-33,870
- Schlusskurs (Vortag)
- Eröffnungskurs
Wichtigste Eigenschaften
Dividenden von Daiichi Sankyo Co. Ltd.
Termine von Daiichi Sankyo Co. Ltd.
- Apr25Daiichi Sankyo Co. Ltd.Q4 2024 Earnings Release
- Jul31Daiichi Sankyo Co. Ltd.Q1 2024 Earnings Release
- Okt30Daiichi Sankyo Co. Ltd.Q2 2024 Earnings Release
Beschreibung
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2021, approximately half of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first U.S approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.